GlobeNewswire Inc | Apr 28, 2021 10:25AM EDT

April 28, 2021

SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncologys (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 8 June.

Abstracts will be available from 5pm US Eastern Time on 19 May 2021. Poster presentations with new and updated data that are not part of the abstract will be released on ASCO.org at the times indicated below and will subsequently be made available on Immuteps website at www.immutep.com.

In addition, Immutep plans to hold a webcast after ASCO to discuss the data and results, as well as to provide an update on the Companys business.

TACTI-002 Posters Results from a phase II study of eftilagimod alpha (soluble LAG-3Title: protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.Session Poster Session: Lung Cancer - Non-Small Cell MetastaticTitle:Date: On demand session available from 9am on 4 June 2021 US Eastern TimePresenter: Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, AustraliaAbstract: 9046 Results from a phase II study of eftilagimod alpha (soluble LAG-3Title: protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.Session Poster Session: Head and Neck CancerTitle:Date: On demand session available from 9am on 4 June 2021 US Eastern TimePresenter: Dr Irene Brana, Investigator, Vall d'Hebron Institute of Oncology, Barcelona, SpainAbstract: 6028 INSIGHT-004 Poster Phase I INSIGHT platform trial: Advanced safety and efficacy dataTitle: from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.Session Poster Discussion Session, Developmental Therapeutics -Title: ImmunotherapyDate: On demand session available from 9am on 4 June 2021 US Eastern Time Thorsten Oliver Goetze, MD; Krankenhaus Nordwest, University CancerPresenter: Center Frankfurt and Institut fr Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, GermanyAbstract: 2518

About American Society of Clinical Oncology (ASCO) ConferenceASCOs annual meeting represents the worlds largest gathering of oncology physicians, industry representatives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care. For additional information on the 2021 ASCOs Annual meeting, please visit https://www.asco.org/

About TACTI-002TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada). The study is evaluating the combination of efti with MSDs KEYTRUDA (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

About INSIGHT-004 (also known as INSIGHT Stratum D)INSIGHT-004 is a Phase I clinical trial and is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immuteps collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialised by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

About Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immuteps current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immuteps large pharmaceutical partners.

Further information can be found on the Companys website www.immutep.comor by contacting:

Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564;tim@lifesciadvisors.com